Oric Pharmaceuticals
ORIC
180 hedge funds and large institutions have $1.34B invested in Oric Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 82 increasing their positions, 41 reducing their positions, and 30 closing their positions.
898% more call options, than puts
Call options by funds: $12.4M | Put options by funds: $1.24M
100% more repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 41
14% more funds holding in top 10
Funds holding in top 10: 7 → 8 (+1)
3% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 30
0.39% more ownership
Funds ownership: 118.93% → 119.32% (+0.39%)
1% less funds holding
Funds holding: 182 → 180 (-2)
11% less capital invested
Capital invested by funds: $1.51B → $1.34B (-$173M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
+$13.9M |
| 2 |
ACM
AIHC Capital Management
Central,
|
+$12.4M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$11.2M |
| 4 |
State Street
Boston,
Massachusetts
|
+$10.8M |
| 5 |
AG
Algert Global
San Francisco,
California
|
+$9.78M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
P
Pfizer
New York
|
-$40M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
-$21.6M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$12M |
| 4 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$8.61M |
| 5 |
Alkeon Capital Management
New York
|
-$6.94M |
ORIC Hedge Fund Activity: Q2 2026 in Review
180 of the 8,296 institutional investors tracked by Wall St. Rank reported a position in Oric Pharmaceuticals (ORIC) for Q2 2026, worth a combined $1.34B — down 11% from $1.51B a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new ORIC positions and 30 closed out — a net gain of 1 holder — while 82 added to existing stakes and 41 trimmed.
The largest buyer was D.E. Shaw & Co, adding an estimated $13.9M. The largest seller was Pfizer, cutting an estimated $40M.
- 180 institutional investors held Oric Pharmaceuticals (ORIC) as of Q2 2026, down from 182 in Q1 2026.
- Funds reported $1.34B of Oric Pharmaceuticals stock for Q2 2026, down 11% quarter-over-quarter.
- 31 funds opened new Oric Pharmaceuticals positions in Q2 2026 and 30 closed out, a net change of +1 holder.
- The largest Oric Pharmaceuticals buyer in Q2 2026 was D.E. Shaw & Co, an estimated $13.9M added.
- The largest Oric Pharmaceuticals seller in Q2 2026 was Pfizer, an estimated $40M sold.
Based on aggregated 13F filings for Q2 2026.